tiprankstipranks
Trending News
More News >
Haw Par Corporation (SG:H02)
:H02
Advertisement

Haw Par (H02) AI Stock Analysis

Compare
36 Followers

Top Page

SG:H02

Haw Par

(OTC:H02)

Select Model
Select Model
Select Model
Outperform 79 (OpenAI - 4o)
Rating:79Outperform
Price Target:
S$17.00
▲(11.77% Upside)
Haw Par's strong financial performance, characterized by high profitability and a solid balance sheet, is the most significant factor contributing to its score. The technical analysis indicates a positive trend, and the valuation is attractive with a reasonable P/E ratio and high dividend yield. The absence of earnings call data and corporate events does not impact the score.

Haw Par (H02) vs. iShares MSCI Singapore ETF (EWS)

Haw Par Business Overview & Revenue Model

Company DescriptionHaw Par Corporation Limited is a Singapore-based company primarily engaged in the healthcare and leisure sectors. Established in 1940, the company is well-known for its flagship product, Tiger Balm, a topical analgesic used for pain relief. Haw Par operates through two main segments: Healthcare, which includes the manufacturing and marketing of medicinal products, and Leisure, which comprises investments in theme parks and real estate. The company is focused on enhancing its product offerings and expanding its market reach both locally and internationally.
How the Company Makes MoneyHaw Par generates revenue primarily through the sale of its healthcare products, with Tiger Balm being a significant contributor to its earnings. The company benefits from a strong brand reputation and a loyal customer base, which helps sustain its sales. Additionally, revenue is supplemented by its investments in leisure properties, including theme parks and real estate holdings, which provide rental income. Strategic partnerships with distributors and retailers also play a crucial role in expanding the company's market presence and driving sales. Furthermore, the company's focus on innovation and product development helps maintain competitive advantage and attract new customers.

Haw Par Financial Statement Overview

Summary
Haw Par exhibits strong financial health with high profitability and a solid balance sheet. The company maintains a robust balance sheet with minimal leverage and financial risk. However, the decline in free cash flow growth warrants attention.
Income Statement
85
Very Positive
Haw Par demonstrates strong profitability with a high net profit margin of 93.24% and consistent revenue growth over the years. The gross profit margin is solid at 54.77%, indicating efficient cost management. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.
Balance Sheet
90
Very Positive
The company maintains a robust balance sheet with a very low debt-to-equity ratio of 0.0087, indicating minimal leverage and financial risk. The return on equity is moderate at 5.50%, reflecting efficient use of equity. The equity ratio is strong, highlighting financial stability.
Cash Flow
75
Positive
Cash flow analysis shows a decrease in free cash flow growth by 8.97%, which could be a concern. However, the free cash flow to net income ratio is high at 93.57%, indicating effective cash generation relative to earnings. The operating cash flow to net income ratio is moderate, suggesting room for improvement in cash flow efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue253.05M244.82M232.06M182.09M141.18M111.03M
Gross Profit141.07M134.09M134.89M98.57M73.64M48.83M
EBITDA252.22M250.11M233.49M49.06M119.45M127.31M
Net Income250.42M228.27M216.57M148.32M110.10M119.77M
Balance Sheet
Total Assets4.21B4.28B3.59B3.65B3.28B2.95B
Cash, Cash Equivalents and Short-Term Investments3.95B3.93B3.21B3.18B596.23M554.41M
Total Debt33.99M36.30M28.48M58.40M762.00K892.00K
Total Liabilities125.21M128.47M117.17M101.41M72.08M64.00M
Stockholders Equity4.08B4.15B3.48B3.55B3.21B2.89B
Cash Flow
Free Cash Flow61.65M50.33M54.92M21.21M14.46M17.49M
Operating Cash Flow64.01M53.79M62.68M40.94M18.84M25.03M
Investing Cash Flow467.65M199.82M258.00M-261.58M87.52M138.09M
Financing Cash Flow-312.00M-82.79M-79.30M-38.07M-65.11M-73.80M

Haw Par Technical Analysis

Technical Analysis Sentiment
Positive
Last Price15.21
Price Trends
50DMA
14.85
Positive
100DMA
14.17
Positive
200DMA
12.80
Positive
Market Momentum
MACD
0.11
Positive
RSI
54.24
Neutral
STOCH
57.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:H02, the sentiment is Positive. The current price of 15.21 is above the 20-day moving average (MA) of 15.12, above the 50-day MA of 14.85, and above the 200-day MA of 12.80, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 54.24 is Neutral, neither overbought nor oversold. The STOCH value of 57.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:H02.

Haw Par Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
S$3.33B13.306.37%9.30%5.85%6.82%
67
Neutral
$1.88B29.016.20%2.58%8.90%4.57%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
43
Neutral
S$1.51B-9.99%12.39%-400.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SG:H02
Haw Par
15.05
4.99
49.66%
SG:BSL
Raffles Medical Group
0.97
0.13
15.61%
SG:A50
Thomson Medical Group Ltd.
0.06
0.01
23.40%
SG:40T
ISEC Healthcare Ltd
0.32
-0.06
-15.79%
SG:5WA
OUE Lippo Healthcare Limited
0.03
0.00
0.00%

Haw Par Corporate Events

Haw Par Corporation Reports Strong Half-Year Earnings
Sep 5, 2025

Haw Par Corporation Limited, a Singapore-based company, is primarily engaged in the licensing of the ‘Tiger’ trademarks and holding strategic investments. It operates in the healthcare, leisure, and investment sectors.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025